Refining Combination Strategies in Metastatic RCC

Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.

EP. 1: Frontline Combination Approaches for Metastatic RCC

March 17th 2021

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.

EP. 2: Personal Approaches to Frontline Therapy for Metastatic RCC

March 17th 2021

Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.

EP. 3: The Phase 3 CLEAR Study in Metastatic RCC

March 17th 2021

Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.

EP. 4: Metastatic RCC: Frontline TKI/IO Safety Data

March 17th 2021

Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.

EP. 5: Implications for Treating Metastatic RCC With TKI/I-O Regimens Upfront

March 17th 2021

Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

EP. 6: Risk Scoring Systems for Metastatic RCC

March 17th 2021

Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.

EP. 7: Future Use of Novel Combinations for Metastatic RCC Treatment

March 17th 2021

Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.

EP. 8: Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

April 21st 2021

This article reviews the results of the phase 3 KEYNOTE-581/CLEAR trial and features expert insights from trial investigators, Robert J. Motzer, MD, and Toni Choueiri, MD.